No Data
No Data
No Data
No Data
No Data
QIAGEN Enhances Bioinformatics Workflows With New Secondary Analysis Solution for Oncology and Inherited Disease Applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances p
GlobeNewswireMay 3 04:05
Qiagen Is Maintained at Hold by Stifel
Qiagen Is Maintained at Hold by Stifel
Dow JonesMay 1 21:33
Stifel Maintains Hold on Qiagen, Lowers Price Target to $45
Stifel analyst Daniel Arias maintains Qiagen with a Hold and lowers the price target from $55 to $45.
Analyst UpgradesMay 1 21:23
Qiagen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 6.31% Stifel $55 → $45 Maintains Hold 02/16/2024 20.48% Morgan Stanley $49.48 → $51 Upgrades Eq
BenzingaMay 1 21:22
Earnings Call Summary | Qiagen NV(QGEN.US) Q1 2024 Earnings Conference
The following is a summary of the Qiagen N.V. (QGEN) Q1 2024 Earnings Call Transcript:Financial Performance:Qiagen reported Q1 2024 net sales of $462 million at constant exchange rates, an improvement
Futu NewsMay 1 08:39 · Conference Call
Deutsche Bank Remains a Buy on Qiagen (QGEN)
TipRanksApr 30 21:36
No Data
No Data